Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Guidelines

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Conferences

Conference Coverage

Conference Listing

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Formulary Central

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Sabrina McCrear is an assistant editor for 

 (AJMC®), which she joined in 2025. She produces written and video content across a range of disease areas and manages social media platforms for 

Sabrina holds a B.A. in Journalism with a minor in Biology from Howard University in Washington, D.C. You can connect with her on 

Videos

Eliot F. Battle, MD, discusses the art of using lasers and energy-based technology to treat patients with skin of color.

Responsible Use of Energy-Based Treatments on Skin of Color: Eliot F. Battle, MD

Jared is a freelance writer for The American Journal of Managed Care® (AJMC®), and previously worked as a senior editor for HCPLive® at MJH Life Sciences®.

He has an MA from University of Sioux Falls. You can connect with Jared on 

Articles

A Mendelian randomization study suggests Actinomyces plays a role in idiopathic pulmonary fibrosis, mediated by circulating inflammatory proteins.

Investigating the Role of Gut Microbiota in IPF

Maggie is a senior editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.

She has a BA in English from Penn State University. You can connect with Maggie on 

Kelley L. Julian, PharmD, BCOP, discusses optimizing myeloma care, addressing barriers in access to intravenous immunoglobulin and innovative therapies at Huntsman Cancer Institute.

Behind the Scenes of Multiple Myeloma Care: A Pharmacist’s View With Kelley L. Julian, PharmD, BCOP

Rose is an associate editorial director at 

She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on 

An innovative artificial intelligence (AI) tool enhanced alopecia areata assessment and improved treatment adherence.

AI–Enhanced SALT Score Improves Accuracy in Alopecia Areata Assessment

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

1.125rem

head of the Department of Clinical Researches at Todua Clinic in Tbilisi, Georgia

Ana Baramidze, MD, head of the Department of Clinical Researches at the Todua Clinic in Tbilisi, Georgia, explained how clinicians can decide how to cemiplimab, which has a low discontinuation rate.

Discontinuation Rates Low in Those Taking Cemiplimab for NSCLC: Ana Baramidze, MD

Cemiplimab demonstrated a 56% overall survival rate, making it a potential option for physicians to use for treating non–small cell lung cancer (NSCLC).

Long-Term Efficacy of Cemiplimab Encourages Flexibility When Treating NSCLC: Ana Baramidze, MD

Cemiplimab plus chemotherapy was found to be consistently effective in treating non-small cell lung cancer (NSCLC) and held up in the EMPOWER-Lung 3 trial.

EMPOWER-Lung 3 Trial Results Find Cemiplimab Plus Chemotherapy Effective in NSCLC: Ana Baramidze, MD